Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

BridgeBio Oncology Therapeutics, Inc.

NASDAQ: BBOT · Life Sciences · 3 alerts · CIK 1869105

Share price
$1.98Close, Nov 16
Market cap
$159M
Shares outstanding
80.25MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BridgeBio Oncology Therapeutics, Inc. filings on SEC EDGAR ↗

4:21 PM ET 10-Q
Financial Results

BridgeBio Oncology Therapeutics Q3 2026 Results: Net Loss of $34.2M, Loss Narrows

BridgeBio Oncology Therapeutics reported a net loss of $34.2 million for the third quarter of 2026, an improvement from the $44.8 million loss in the prior year period. Total assets decreased to $346.2 million from $448.4 million at year-end 2025, primarily driven by a significant reduction in cash and cash equivalents as the company continues to fund its research and development operations.

Key figure
Net loss $34.2M
4:19 PM ET 8-K
Financial Results

BridgeBio Oncology Therapeutics Financial Results

BridgeBio Oncology Therapeutics reported financial results for the third quarter of 2026, highlighting a cash runway expected to fund operations into 2029. The company reported clinical progress for its RAS-pathway inhibitors, including a 75% objective response rate for BBO-8520 in combination with pembrolizumab in certain lung cancer patients. Management expects monotherapy data updates for BBO-11818 and BBO-10203 in the fourth quarter of 2026.

Term
Q3 2026

“The third quarter was an important period for BBOT as we reported updated clinical data for BBO-8520 and delineated our strategic focus. Driven by encouraging clinical data across all three programs we are executing on multiple combinations with the potential for significant patient benefit.”

Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT

“With a strong balance sheet, multiple data catalysts expected through mid-2027, and cash runway into 2029, we believe BBOT is well positioned to advance differentiated therapies for patients with KRAS-driven cancers.”

Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.